TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from EMvision Medical Devices Ltd. ( (AU:EMV) ) is now available.
EMVision Medical Devices Ltd has commenced a Pre-Hospital Mobile Stroke Unit (MSU) Study in Melbourne to evaluate their First Responder Brain Scanner. This study, conducted in collaboration with the Australian Stroke Alliance, Ambulance Victoria, and the Royal Melbourne Hospital, aims to assess the usability and workflow integration of the device in a real-world MSU setting. The study is significant as it seeks to address the need for scalable pre-hospital stroke care solutions, potentially impacting the company’s market positioning by advancing the development and validation of their device through the FDA 510(k) regulatory pathway.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
More about EMvision Medical Devices Ltd.
EMVision Medical Devices Ltd is a company operating in the medical device industry, focusing on developing innovative diagnostic tools. Their primary product is the First Responder Brain Scanner, which aims to enhance pre-hospital stroke care by providing rapid, portable neurodiagnostic capabilities.
Average Trading Volume: 47,309
Technical Sentiment Signal: Buy
Current Market Cap: A$164.2M
Find detailed analytics on EMV stock on TipRanks’ Stock Analysis page.